Shares of Zydus Lifesciences Ltd are trading flat after hitting a day’s high of Rs 888 on 20th January, despite the company saying it is in talks to acquire US biopharma firm Ardelyx.

Zydus Life may acquire a controlling stake in Ardelyx or buy key molecules. The company is considering raising funds through a qualified institutional placement (QIP) to partly fund the deal.

Ardelyx currently has a market capitalisation of $1.6 billion.

Zydus Life’s board had approved raising to Rs 5,000 crore through the QIP on 6th November, 2025. The primary aim of the QIP is to deleverage the company’s balance sheet by reducing existing debt.

The company is also exploring opportunities in its US speciality business, particularly in gastroenterology. Additionally, it is exploring opportunities in the central nervous system (CNS) and cardiology segments.

Ardelyx has two US-approved commercial products: IBSRELA (tenapanor) for adults with irritable bowel syndrome with constipation, and XYPHOZAH (tenapanor) for adults with chronic kidney disease. IBSRELA is expected to generate $410–430 million in revenue in 2026. Furthermore, projections reach $1 billion by 2029.

At 12:59 PM, shares of Zydus Life were trading 0.25% lower at Rs 878.90 on NSE.

Tradz by EquityPandit leverages advanced AI technology to provide you with powerful market predictions and actionable stock scans. Download the app today and 10x your trading & investing journey!